Rapid and simple determination of plasma and erythrocyte MDA levels in prostate cancer patients by a validated HPLC method

Journal of Liquid Chromatography and Related Technologies

Volumn 30, Issue 16, 2007, Pages 2435-2444

  Arsova Sarafinovska, Zorica ^a   Aydin, Ahmet ^b   Sayal, Ahmet ^b   Eken, Ayşe ^b   Erdem, Onur ^b   Savaser, Ayhan ^b   Erten, Koray ^b   Özgök, Yaşar ^b   Dimovski, Aleksandar ^c  

^a Republic Institute for Health Protection   (Macedonia)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c SS Cyril and Methodius University Faculty of Pharmacy   (Macedonia)

Author keywords

HPLC; Lipid peroxidation; Oxidative stress; Prostate cancer

Indexed keywords

DISEASES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OXIDATIVE STRESS; PATIENT MONITORING; PLASMA (HUMAN); PURIFICATION; SENSITIVITY ANALYSIS;

CHROMATOGRAPHIC SYSTEMS; ERYTHROCYTES; LIPID PEROXIDATION; PROSTATE CANCERS;

TUMORS;

MALONALDEHYDE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PURIFICATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 34547154381     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070701465720     Document Type: Article

References (31)

1. Jemal, A.; Tiwari, R.C.; Murray, T.; et al. Cancer statistics, 2004. CA Cancer J. Clin. 2004, 54, 8-29.
2. Moul, J.W.; Anderson, J.; Penson, D.F.; Klotz, L.H.; Soloway, M.S.; Schulman, C.C. Early prostate cancer: Prevention, treatment modalities, and quality of life issues. Eur. Urol. 2003, 44, 283-93.
3. Nelson, W.G.; DeMarzo, A.M.; Isaacs, W.B. Prostate cancer. NEJM Mechanisms of Disease 2003, 349, 366-81.
4. Ripple, M.O.; Henry, W.F.; Rago, P.R.; Wilding, G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J. Natl. Cancer Inst. 1997, 89, 40-8.
5. Oberley, T.D.; Oberley, L.W. Oxygen radicals and cancer. In Free Radicals in Aging; Yu, B.P. (Ed.); CRC Press: Boca Raton, FL, 1993, 247-6.
6. Dotan, Y.; Lichtenberg, D.; Pinchuk, I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Progress in Lipid Research 2004, 1-28.
7. Draper, H.H.; Hadley, M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990, 186, 421-31.
8. Badcock, N.R.; Zoanetti, G.D.; Martin, E.S. Nonchromatographic assay for malondialdehyde-thiobarbituric acid adduct with HPLC equivalence. Clin. Chem. 1997, 43, 1655-57.
9. Nielsen, F.; Mikkelsen, B.B.; Nielsen, J.B.; Andersen, H.R.; Grandjean, P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin. Chem. 1997, 43 (7), 1209-1214.
10. Fukunaga, K.; Yoshida, M.; Nakazono, N. A simple, rapid, highly sensitive and reproducible quantification method for plasma malondialdehyde by highperformance liquid chromatography. Biomed. Chromatograph 1998, 12, 300-303.
11. Lykkesfeldt, J. Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: Comparision with Ultraviolet-Visible Spectrophotometry. Clin. Chem. 2001, 47 (9), 1725-1727.
12. Volpi, N.; Tarugi, P. Improvement in the high-performance liquid chromatography malondialdehyde level determination in normal human plasma. J. Chromat. B, 1998, 713, 433-437.
13. Templar, J.; Kon, S.P.; Milligan, T.P.; Newman, D.J.; Raftery, M. Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Nephrol. Dial. Transplant 1999, 14, 946-951.
14. Pilz, J.; Meineke, I.; Gleiter, C.H. Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative. J. Chromat. B, 2000, 742, 315-325.
15. Claeson, K.; Thorsen, G.; Karlberg, B. Methyl malondialdehyde as an internal standard for the determination of malondialdehyde. J. Chromat. B, 2001, 751, 315-323.
16. Larstad, M.; Ljungkvist, G.; Olin, A.C.; Toren, K. Determination of malondialdehyde in breath condensate by high-performance liquid chromatography with fluorescence detection. J. Chromat. B 2001, 766, 107-114.
17. Agarwal, R.; Chase, S.D. Rapid fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J. Chromat. B 2002, 775, 121-126.
18. Karatas, F.; Karatepe, M.; Baysar, A. Determination of free malondialdehyde in human serum by high-performance liquid chromatography. Anal. Biochem. 2002, 311, 76-79.
19. Li, K.; Shang, X.; Chen, Y. High-performance liquid chromatographic detection of lipid peroxidation in human seminal plasma and its application to male infertility. Clin. Chem. Acta. 2004, 346, 199-203.
20. Lepage, G.; Munoz, G.; Champagne, J.; Roy, C.C. Preparative steps necessary for the accurate measurement of malondialdehyde by high-performance liquid chromatography. Anal. Biochem. 1991, 197, 277-283.
21. Draper, H.H.; Squires, E.J.; Mahmoodi, H.; Wu, J.; Agarwal, S.; Hadley, M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic. Biol. Med. 1993, 15 (4), 353-63.
22. Londero, D.; Lo, G.P. Automated high-performance liquid chromatographic separation with spectrofluorometric detection of a malondialdehyde- thiobarbituric acid adduct in plasma. J. Chromatogr. A 1996, 729, 207-210.
23. Diaz-Velez, C.R.; Garcia-Castineiras, S.; Mendoza-ramos, E.; et al. Increased malondialdehyde in periferal blood of patients with congestive heart failure. Am Heart J. 1996, 131, 146-152.
24. Dasgupta, A.; Hussain, S.; Ahmad, S. Increased lipid peroxidation in patients on maintenance haemodialysis. Nephron. 1992, 60, 56-59.
25. Olinski, R.; Zastawny, T.H.; Foksinski, M.; Barecki, A.; Dizdaroglu, M. DNA base modifications and antioxidant enzyme activities in human benign prostate hyperplasia. Free. Radic. Biol. Med. 1995, 18, 807-813.
26. Das, U.N.; A radical approach to cancer. Med. Sci. Monit. 2002, 8, RA79-92.
27. Biri, H.; Ozturk, H.S.; Kacmaz, M.; Karaca, K.; Tokucoglu, H.; Durak, I. Activities of DNA turnover and free radical metabolizing enzymes in cancerous human prostate tissue. Cancer Invest. 1999, 17, 314-9.
28. Yilmaz, M.I.; Saglam, K.; Sonmez, A.; et al. Antioxidant system activation in prostate cancer. Biol. Trace. Elem. Res. 2004, 98, 13-9.
29. Dogru-Abassoglu, S.; Aykac-Toker, G.; Kocak, T.; Unluer, E.; Uysal, M. Antioxidant enzyme activities and lipid peroxides in the plasma of patients with benign prostatic hyperplasia or prostate cancer are not predictive. J. Cancer Res. Clin. Oncol. 1999, 125, 402-4.
30. Kumaraguruparan, R.; Subapriya, R.; Kabalimoorthy, J.; Nagini, S. Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast. Clin. Biochem. 2002, 35, 275-9.
31. Ripple, M.; Mulcahy, R.T.; Wilding, G. Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cells. J. Urol. 1993, 150, 209-14.